GSK application for myeloma treatment accepted by EMA
19th Jul 2024 12:33
(Sharecast News) - GSK announced on Friday that the European Medicines Agency (EMA) has accepted its marketing authorisation application for 'Blenrep', or belantamab mafodotin, in combination with bortezomib plus dexamethasone - 'BorDex', or pomalidomide plus dexamethasone - PomDex, for treating relapsed or refractory multiple myeloma.
Read moreCiti cuts GSK target price after Arexy disappointment, but stays at 'buy'
5th Jul 2024 08:33
(Sharecast News) - Citi has reiterated its 'buy' rating on GSK despite a flurry of disappointing news for the biopharma giant in recent weeks, though the bank has slashed its target price for the stock by more than 10%.
Read moreGSK restructures vaccine collaboration with CureVac
3rd Jul 2024 09:45
(Sharecast News) - GSK announced on Wednesday that it has restructured its collaboration with CureVac into a new licensing agreement, granting GSK exclusive rights to develop, manufacture, and globally commercialise mRNA-based candidate vaccines for influenza and Covid-19.
Read moreLondon close: Stocks fall on EU inflation, US jobs data
2nd Jul 2024 17:24
(Sharecast News) - London stocks closed lower on Tuesday as investors digested eurozone inflation data and a modest increase in US job openings.
Read moreLondon close: Stocks mixed ahead of key UK, US data
27th Jun 2024 15:48
(Sharecast News) - London stocks ended Thursday's trading session with a mixed performance as market participants awaited crucial US inflation data and UK GDP figures set to be released later in the week.
Read moreGSK shares drop as US narrows recommendations for RSV vaccines
27th Jun 2024 09:58
(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for the company's Arexvy product.
Read moreGSK reports regulatory progress for Omjjara, Jemperli
24th Jun 2024 07:21
(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.
Read moreZantac litigation fears overdone at GSK, says Shore Capital
11th Jun 2024 14:31
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.
Read moreGSK launches appeal to recent Zantac ruling
11th Jun 2024 07:22
(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.
Read moreGSK's Arexvy vaccine approved for wider age range
10th Jun 2024 07:17
(Sharecast News) - US regulators have approved the use of GSK's Arexvy vaccine for a younger age group, the biopharma group announced on Monday.
Read moreGSK to appeal Delaware ruling on jury trials in Zantac cancer cases
3rd Jun 2024 07:30
(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.
Read moreLondon close: Stocks mixed after disappointing retail sales data
24th May 2024 15:19
(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted to a larger-than-expected drop in UK retail sales.
Read moreJury rules in favour of GSK in Zantac trial
24th May 2024 07:30
(Sharecast News) - A court in Illinois has ruled in favour of GSK in the first Zantac case to go to trial, the UK drugs giant confirmed on Friday.
Read moreGSK reports promising results from asthma treatment trials
21st May 2024 07:21
(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.
Read moreLondon close: Stocks recoup some earlier losses
17th May 2024 15:52
(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.
Read more